# Myasthenia Gravis, Generalized FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/myasthenia-gravis-generalized

> 4 upcoming FDA catalysts in myasthenia Gravis, Generalized: claseprubart (DNTH) on December 2028 (primary completion); claseprubart (DNTH) on Dec 2028 to Mar 2029 (topline data readout); povetacicept (VRTX) on Mar to Jun 2029 (topline data readout); povetacicept (VRTX) on March 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 28, 2025 | [Claseprubart primary completion](https://sec-api.dev/pdufa/claseprubart) | DNTH | Myasthenia Gravis, Generalized | completed | "NCT06282159 (A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Dianthus Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06282159)) |
| January 5, 2026 | [Descartes-08 primary completion](https://sec-api.dev/pdufa/descartes-08) | RNAC | Myasthenia Gravis, Generalized | completed | "NCT04146051 (Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Cartesian Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04146051)) |
| December 2028 | [Claseprubart primary completion](https://sec-api.dev/pdufa/claseprubart) | DNTH | Myasthenia Gravis, Generalized | scheduled | "NCT07647510 (A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Dianthus Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07647510)) |
| Dec 2028 to Mar 2029 | [Claseprubart topline data readout](https://sec-api.dev/pdufa/claseprubart) | DNTH | Myasthenia Gravis, Generalized | scheduled | "NCT07647510 (A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Dianthus Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07647510)) |
| Mar to Jun 2029 | [Povetacicept topline data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX | Myasthenia Gravis, Generalized | scheduled | "NCT07501702 (A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07501702)) |
| March 2029 | [Povetacicept primary completion](https://sec-api.dev/pdufa/povetacicept) | VRTX | Myasthenia Gravis, Generalized | scheduled | "NCT07501702 (A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07501702)) |

## Drugs

- [Claseprubart](https://sec-api.dev/pdufa/claseprubart) (DNTH)
- [Descartes-08](https://sec-api.dev/pdufa/descartes-08) (RNAC)
- [Povetacicept](https://sec-api.dev/pdufa/povetacicept) (VRTX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/myasthenia-gravis-generalized.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Myasthenia Gravis, Generalized FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/myasthenia-gravis-generalized

```bibtex
@misc{secapidev_indications_myasthenia_gravis_generalized_20261116,
  title        = {Myasthenia Gravis, Generalized FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/myasthenia-gravis-generalized}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_myasthenia_gravis_generalized_20261116","title":"Myasthenia Gravis, Generalized FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/myasthenia-gravis-generalized","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
